Patents Assigned to QIAGEN GmbH
  • Patent number: 10648031
    Abstract: The present invention is directed to novel methods and kits to be employed for preparing adapter-ligated amplicons or a sequencing library of a target DNA, respectively.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: May 12, 2020
    Assignee: QIAGEN GmbH
    Inventors: Nan Fang, Dirk Loeffert
  • Patent number: 10633697
    Abstract: The invention is in the field of regulation of enzymatic activity in nucleic acid modifying reactions. It describes a method of regulating enzymatic activity by adding chelating agents to the reaction composition and exploits the fact that both the binding of divalent cations to these chelating agents and the pH of commonly used buffers is temperature dependent. PCR experiments that are hampered by non-specific side products can be regulated such that the target sequence is amplified in a more specific manner.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: April 28, 2020
    Assignee: Qiagen GmbH
    Inventors: Alexander Azzawi, Ralf Peist
  • Patent number: 10634588
    Abstract: The present invention relates to a reagent for the disruption of cell material, containing an internal standard that is completely integrated into the reagent for control and evaluation of the completeness of disruption of the cell material and subsequent steps, comprising a step selected from sample preparation, extraction, enrichment, isolation, purification, reverse transcription, amplification and detection of the cell components obtained from the disrupted cells, or a combination of a plurality or all of these steps.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: April 28, 2020
    Assignee: QIAGEN GmbH
    Inventors: Dirk Heckel, Katharina Beller
  • Patent number: 10614571
    Abstract: System and method for distinguishing at least one first object from at least one second object in a plurality of digital images is provided. The at least one first object having received at least one molecule comprising genetic information, the at least one second object not having received a molecule comprising genetic information. The at least one molecule is configured to receive one of a plurality of fluorescent compounds in each of a plurality of cycles. The digital images being determined by an optical imaging system during emission of electromagnetic radiation by the fluorescent compounds, wherein the plurality of digital images comprises a plurality of series of images, each image of a series referring to the emission spectrum of a respective fluorescent compound and wherein the series of images is repeatedly taken for each of the plurality of cycles.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 7, 2020
    Assignee: QIAGEN GmbH
    Inventors: Thomas Unterer, Guido Schuster
  • Patent number: 10538809
    Abstract: Short tandem repeat (STR) markers are genetic elements that are frequently used in the fields of forensic analysis, paternity determination and detection of genetic diseases and cancers. Such analysis involves the amplification of STR loci. Technically, this can be challenging due to sequence variations in the flanking regions of the locus. In the case of SE33, previous amplification efforts have failed. The present invention describes a set of primers for the amplification of SE33 and a method for the analysis of the presence and/or level of SE33, also in combination with other STRs.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: January 21, 2020
    Assignee: QIAGEN GMBH
    Inventors: Daniel Müller, Sascha Strauss
  • Patent number: 10514330
    Abstract: The present invention refers to a device, comprising a hollow body having at least one open end comprising at least one solid matrix binding, adsorbing, absorbing, chelating or retaining compounds which are not desired in a sample and preferably at least one barrier which is non-permeable for liquids and solids under ambience conditions, however, becomes liquid-permeable by applying an external force to the barrier, the use of such a device for isolating or purifying a biomolecule from a sample, a method for preparation of the device and a method for isolation or purification of any biomolecule using said device.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: December 24, 2019
    Assignee: QIAGEN GmbH
    Inventors: Vera Holländer, Markus Müller, Karin Schulte
  • Patent number: 10501783
    Abstract: The present invention relates to methods and uses for the detection or quantification of newly-synthesized double-stranded target nucleic acid molecules in a sample during quantitative real-time polymerase chain reaction (qPCR) amplification. According to the invention, an intercalating dye recognizing double-stranded DNA molecules with higher affinity than single-stranded DNA molecules and a fluorophore-labeled oligonucleotide-probe being sequence specific for a target nucleic acid molecule are simultaneously employed, thus enabling quantification a specific target and total amount of a mixed nucleic acid population, and enabling assessing the cause of suboptimal PCR performance.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: December 10, 2019
    Assignee: QIAGEN GMBH
    Inventors: Nan Fang, Andreas Missel, Katja Heitz, Holger Wedler
  • Patent number: 10458998
    Abstract: Device for sample processing, particularly sample conditioning as well as for the preparation and/or optionally for implementing a sequential process for an analyte from a biological sample, said device comprising a module for receiving and/or outputting at least one sample vessel or process vessel, a module for transporting a process vessel, a module for sample conditioning and a module for initiating a sequential process for an analyte. The modules are divided into at least two units that each possesses a control system, and which are connected through a first data bus.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: October 29, 2019
    Assignee: QIAGEN GMBH
    Inventors: Magnus Alfredsson, Konstantin Lutze, Thomas Deutschmann, Patrick Widler, Samuel Farner, Ulf Friederichs, Axel Bützer, Jürg Aeschbacher, Bruno Walder
  • Patent number: 10407713
    Abstract: The present invention provides a special reagent for the pretreatment of sample materials. The pretreatment with the reagent according to the invention enables the isolation of nucleic acids by a uniform method from very diverse sample materials, in particular different bioprocess samples, even if the nucleic acids are only present in small amounts in the sample materials. The reagent used for the pretreatment comprises, as key component, at least one compound comprising an amino group. The invention further relates to methods of purification of nucleic acids, in which the sample material is pretreated correspondingly, and suitable kits.
    Type: Grant
    Filed: July 4, 2012
    Date of Patent: September 10, 2019
    Assignee: QIAGEN GmbH
    Inventor: Peter Porschewski
  • Patent number: 10400288
    Abstract: The present application concerns a new in vitro method for assessing the risk that a subject suffers from prostate cancer.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: September 3, 2019
    Assignees: Aarhus Universitet, Region Midtjylland, QIAGEN GmbH
    Inventors: Anni Rønfeldt Thomsen, Jacob Christian Fredsøe, Karina Dalsgaard Sørensen, Lars Kongsbak, Peter Mouritzen, Torben Ørntoft
  • Publication number: 20190259137
    Abstract: Method and system for compensating intensity biases in a plurality of digital images. Each digital image of the plurality of digital images contains a plurality of objects and each of the plurality of objects is configured to receive at least one molecule comprising genetic information, wherein the at least one molecule is configured to receive one of at least a first fluorescent compound and a second fluorescent compound. A first digital image of the plurality of digital images is taken by an optical imaging system during emission of electromagnetic radiation by the first fluorescent compound, and a second digital image of the plurality of digital images is taken by the optical imaging system during emission of electromagnetic radiation by the second fluorescent compound.
    Type: Application
    Filed: October 20, 2017
    Publication date: August 22, 2019
    Applicant: QIAGEN GmbH
    Inventors: Thorsten ZERFASS, Maiko LOHEL, Fernando Carrillo OESTERREICH
  • Patent number: 10376887
    Abstract: Closing arrangement for a cap of a tube in a carrier, wherein the arrangement comprises at least a first, a second and a third moveable engagement member, the first member being adapted to induce a first part of the cap rotation and the second member being adapted to induce a second part of the cap rotation and the third member being adapted to induce a third part of the cap rotation for closure.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: August 13, 2019
    Assignee: Qiagen GMBH
    Inventors: Bruno Walder, Sasa Lazevski, Kurt Stark
  • Patent number: 10358681
    Abstract: The present application concerns a new in vitro method for assessing the prognosis of a prostate cancer patient, comprising measuring the expression level of at least two miRs selected from group of miRs consisting of: miR-106a-5p, miR-10b-5p, miR-133a-3p, mi R-152-3p, miR-185-5p, miR-193a-5p, miR-221-3p, miR-23a-3p, miR-30d-3p, miR-326, mi R-374b-5p, miR-615-3p and mi R-625-3p in a RNA sample from prostate cells obtained from said patient, wherein a changed expression level of said at least 2 miRs, as compared to a reference expression profile, is indicative of the prognosis of said prostate cancer patient.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: July 23, 2019
    Assignees: Aarhus Universitet, Region Midtjylland, QIAGEN GmbH
    Inventors: Anni Rønfeldt Thomsen, Helle Kristensen, Karina Dalsgaard Sørensen, Lars Kongsbak, Peter Mouritzen, Torben Ørntoft
  • Patent number: 10329553
    Abstract: The present invention provides a method for isolating RNA including small RNA having a size of 200 nt or less from a sample, comprising the following steps: a) providing a composition comprising RNA and a chaotropic agent; b) adding alcohol; c) incubating the mixture for at least 2 min; d) adding additional alcohol to the mixture to adjust the overall alcohol concentration in the mixture to ?50%; e) binding RNA contained in the mixture to a nucleic acid binding solid phase; f) optionally washing the bound RNA; g) optionally eluting RNA from the solid phase. Due to the step-wise addition of alcohol, the overall RNA yield and the yield of small RNA is improved.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: June 25, 2019
    Assignee: QIAGEN GmbH
    Inventors: Martin Schlumpberger, Stefanie Schröer, Vera Holländer
  • Patent number: 10323273
    Abstract: The present invention relates to methods and uses where a combination of (i) an enzyme exhibiting 5??3? exonuclease activity and specifically degrading 5?-phosphorylated strands of double-stranded nucleic acids is used, and (ii) one or more primer pair(s), each primer being 5? phosphorylated, in a method comprising at least a first and a second amplification reaction of a first and a second template, respectively, for preventing contamination of the second amplification reaction with amplification products of the first amplification reaction, as well as novel methods and kits using the combination. Also, the present invention relates to kits comprising the enzyme and either 5?-phosphorylated primers or a polynucleotide kinase.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: June 18, 2019
    Assignee: Qiagen GmbH
    Inventors: Nan Fang, Dirk Loeffert, Christine Runde
  • Patent number: 10273470
    Abstract: The present invention pertains to a method for isolating RNA, including small RNA from a RNA and DNA containing sample, wherein the sample is lysed and the optionally further processed lysate is incubated with a DNase to degrade DNA prior to purifying the RNA from the optionally further processed lysate. It was found that performing the DNase digest prior to isolating the RNA from the lysate has considerable advantages.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: April 30, 2019
    Assignee: QIAGEN GmbH
    Inventors: Vera Holländer, Gabriele Christoffel
  • Patent number: 10233508
    Abstract: The present disclosure provides methods, compositions and devices for isolating virus particles and/or viral nucleic acids from body samples that were stabilized using a stabilizing composition comprising a formaldehyde releaser agent.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: March 19, 2019
    Assignee: QIAGEN GmbH
    Inventors: Martin Horlitz, Markus Sprenger-Haussels, Annabelle Schubert, Uwe Oelmüller
  • Patent number: 10227378
    Abstract: The present invention pertains to a method for loading a crystallization device and for manufacturing a crystallization device comprising multiple receptacles with a pre-defined amount of at least one matrix-forming compound capable of forming a crystallization matrix for a membrane protein, said method comprising the following steps: a) Modifying the state of aggregation of said at least one matrix-forming compound to a fluidic state which allows dispensing said at least one matrix-forming compound, and b) dispensing a defined amount of said at least one matrix-forming compound into at least one receptacle of the crystallization device, wherein said dispensed matrix-forming compound solidifies within said receptacle. Thereby prefilled crystallization devices are obtained which can be used as consumables in particular in automated crystallization processes. Also provided are protein crystallization methods using respectively prepared crystallization devices.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: March 12, 2019
    Assignees: CUBE BIOTECH GmbH, QIAGEN GmbH
    Inventors: Johann Kubicek, Frank Schaefer, Joerg Labahn, Georg Bueldt
  • Patent number: 10221445
    Abstract: The present invention refers to a method, a composition and a kit for isolating biomolecules from any biological sample material containing cells, virus(es), microorganism(s) or a combination thereof comprising a cell- or virus-simulating means, wherein said cell- or virus-simulating means comprises at least one type of marker molecule(s), incorporated in at least one type of a layer, capsule, bead, sphere or particle, which is not a biological cell or provided on a substrate covered by a coating.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: March 5, 2019
    Assignees: QIAGEN GmbH, QIAGEN Hamburg GmbH
    Inventors: Katharina Beller, Thomas Doedt, Dirk Heckel, Rainer Söller
  • Patent number: 10184145
    Abstract: The present invention pertains to a method for isolating extracellular nucleic acids from a sample, wherein said sample is optionally stabilized, by binding the extracellular nucleic acids to a solid phase which carries anion exchange groups, comprising the following steps: binding the extracellular nucleic acids to the solid phase in a binding mixture having a first pH which allows binding the extracellular nucleic acids to the anion exchange groups of the solid phase; wherein the sample makes up at least 85% of the volume of the binding mixture; separating the solid phase with the bound extracellular nucleic acids; optionally washing the extracellular nucleic acids; optionally eluting extracellular nucleic acids from the solid phase. The method has the advantage that large sample volumes can be processed and that extracellular nucleic acids can be isolated rapidly with a high yield. The method is particularly suitable for automatable processes.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: January 22, 2019
    Assignee: QIAGEN GmbH
    Inventors: Martin Horlitz, Annette Nocon, Markus Sprenger-Haussels, Peter Grünefeld, Christoph Erbacher